Expanding Test Menus: A Compliance Roadmap for FDA-Regulated Labs
Two OIG advisory opinions guide laboratories that want to work with pharma or medical device companies on expanded testing
Two OIG advisory opinions guide laboratories that want to work with pharma or medical device companies on expanded testing
A lawyer advises medical laboratories on how to improve their avenues for reporting unethical behavior
Judge rules that the FDA has ‘no authority’ to issue its rule governing laboratory-developed tests
Changes ‘have had a significant impact on the recruitment process for laboratory directors and technical supervisors,’ recruiter says
A proposed move to make noncompete agreements illegal could impact retention of some laboratory employees.
A look at the US end-of-emergency game plan and how it will impact lab compliance.
The year was certainly an interesting one in terms of regulatory change in the medical laboratory space.
After the price transparency rules took effect in January 2021, CMS finally issued the first penalties for violations.
CMS recently announced some important changes affecting PAMA price reporting, along with a list of 17 new PLA codes that will be recognized.